30 closest matches · ranked by relevance
Leukemia · Myelodysplastic Syndrome · Lymphoma
Primary: Percent of Engrafted Participants With Successful Neutrophil Recovery — 96 % w/incidence of neutrophil recovery
Leukemia · Myeloproliferative Disorders · Myelodysplastic-Myeloproliferative Diseases
Primary: Two-year Overall Survival — 46; 51 percentage of patients
Hematologic Malignancies
Primary: Overall Survival of Participants — 13 participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Lymphoma, Non-Hodgkin
Primary: Number of Donors Requiring a Second Collection to Obtain a Minimum CD34/Kg (2 x 10^6) Necessary for Allogeneic Stem Cell Transplantation — 4 Participants
B-Cell Prolymphocytic Leukemia · Hypodiploidy · Loss of Chromosome 17p
Primary: Event-Free Survival (EFS) — 9 Participants
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Rates of Durable Engraftment — 17.9; 15.75; 13; 18.25 days
Sickle Cell Disease
Primary: Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events — 14 Participants
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 83.7; 62.0 percentage of participants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Graft Rejection — 3 Participants
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA) · Severe Aplastic Anemia (SAA)
Primary: Number of Participants Who Engrafted by Day 42 — 30 Participants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
Healthy
Primary: Change in Cytokine Gene Expression Profiles (84 Genes) in T Cells Following G-CSF Administration — 16 unique cytokine genes affected
Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia · Burkitt's Lymphoma
Primary: Percentage of Participants With Progression Free Survival (PFS) — 35.0; 41.1 percentage of participants — p=0.4092
Hematologic Malignancy · Myelodysplastic Syndrome (MDS) · Aplastic Anemia
Primary: The Number of Participants Reaching Primary Endpoint of Absolute Neutrophil Count (ANC) of 500/uL (Engraftment). — 3 participants
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
Immunodeficiencies
Primary: Number of Participants With Successful Engraftment — 87; 5 Participants
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Lymphoma · Myeloma · Leukemia
Primary: Toxicity — 21; 25 participants
Leukemia · Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count Engraftment — 21 participant
Malignant Diseases · Non-malignant Diseases
Primary: Number of Patients With Severe (Grade III/IV) Acute Graft vs Host Disease (GVHD) — 0 Participants
Hematologic Malignancy
Primary: Proportion of Patients Undergoing an Allo HCT Transplant Who Have a KIR Favorable Donor. — 23; 21 Participants
Lymphoma · Myeloma · Leukemia
Primary: Toxicity — 5; 3; 10; 17 participants
Dyskeratosis Congenita · Aplastic Anemia
Primary: Incidence of Neutrophil Engraftment — 100; 100; 96; 100 Percentage of participants
Anemia, Aplastic · Amegakaryocytic Thrombocytopenia · Diamond-Blackfan Anemia
Primary: Treatment Failures
Acute Lymphoblastic Leukemia · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: The Incidence of Durable Hematopoietic Engraftment for T-cell Depleted Transplants Fractionated by the CliniMACS System Administered After Each of the Four Disease…
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Patients With Day 100 Transplant-related Mortality — 1 Participants
Blood Cancer · Leukemia · Graft Versus Host Disease
Primary: Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and…
Refractory Multiple Myeloma
Primary: PFS — 4; 1 Participants